Forte Biosciences announces oversubscribed $53 million private placement

seekingalpha

2024-11-20

Forte Biosciences (NASDAQ:FBRX) on Wednesday announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102.
"We expect to advance FB102 into additional indications over the next 12 months. 2025 could be an exciting year of clinical milestones for FB102," said Paul Wagner, Chief Executive Officer of Forte Biosciences.
FBRX +19.49% premarket to $7.08.
Source: Press Release

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2484170991"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484170991\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2484170991?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 22:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484170991","market":"nz","top_or_hot":-1,"title":"Forte Biosciences announces oversubscribed $53 million private placement","media":"seekingalpha","content":"<html><body><ul> <li>Forte Biosciences (<span>NASDAQ:FBRX</span>) on Wednesday announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102.</li> <li>\"We expect to advance FB102 into additional indications over the next 12 months. 2025 could be an exciting year of clinical milestones for FB102,\" said Paul Wagner, Chief Executive Officer of Forte Biosciences.</li> <li>FBRX  <font color=\"green\">+19.49%</font> premarket to  $7.08.</li>\n<li>Source: Press Release\n</li>\n</ul></body></html>","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences announces oversubscribed $53 million private placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences announces oversubscribed $53 million private placement\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2024-11-20 22:18</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><ul> <li>Forte Biosciences (<span>NASDAQ:FBRX</span>) on Wednesday announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102.</li> <li>\"We expect to advance FB102 into additional indications over the next 12 months. 2025 could be an exciting year of clinical milestones for FB102,\" said Paul Wagner, Chief Executive Officer of Forte Biosciences.</li> <li>FBRX  <font color=\"green\">+19.49%</font> premarket to  $7.08.</li>\n<li>Source: Press Release\n</li>\n</ul></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://seekingalpha.com/news/4311776-forte-biosciences-announces-oversubscribed-53-million-private-placement\">seekingalpha</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FBRX","symbol_name":"Forte BioSciences Inc","start_time":0,"source_url":"https://seekingalpha.com/news/4311776-forte-biosciences-announces-oversubscribed-53-million-private-placement","article_id":"2484170991","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484170991","pubTimestamp":1732112294,"columns":[],"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Forte Biosciences  on Wednesday announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102. \"We expect to advance FB102 into additional indications over the next 12 months. 2025 could be an exciting year of clinical milestones for FB102,\" said Paul Wagner, Chief Executive Officer of Forte Biosciences. FBRX  +19.49% premarket to  $7.08.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"FBRX":"Forte BioSciences Inc","BK4139":"生物科技"},"translate_title":"Forte Biosciences宣布超额认购5300万美元私募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBRX":0.9},"content_text":"Forte Biosciences (NASDAQ:FBRX) on Wednesday announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102. \"We expect to advance FB102 into additional indications over the next 12 months. 2025 could be an exciting year of clinical milestones for FB102,\" said Paul Wagner, Chief Executive Officer of Forte Biosciences. FBRX  +19.49% premarket to  $7.08.\nSource: Press Release","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}